HemoHIM enhances the therapeutic efficacy of ionizing radiation treatment in tumor-bearing mice.
Although radiotherapy is commonly used for a variety of cancers, radiotherapy alone does not achieve a satisfactory therapeutic outcome. In this study, we examined the possibility that HemoHIM can enhance the anticancer effects of ionizing radiation (IR) in melanoma-bearing mice. The HemoHIM was prepared by adding the ethanol-insoluble fraction to the total water extract of a mixture of three edible herbs-Angelica Radix, Cnidium Rhizoma, and Paeonia Radix. Anticancer effects of HemoHIM were evaluated in melanoma-bearing mice exposed to IR. IR treatment (5 Gy at 7 days after melanoma cell injection) reduced the weight of the solid tumors, and HemoHIM supplementation with IR enhanced the decreases in tumor weight (P < .03). In the melanoma-bearing mice treated with IR, HemoHIM administration also increased the activity of natural killer cells and cytotoxic T cells, although the proportions of these cells in spleen were not different. In addition, HemoHIM administration increased the interleukin-2 and tumor necrosis factor-alpha secretion from lymphocytes stimulated with concanavalin A, which seemed to contribute to the enhanced efficacy of HemoHIM in tumor-bearing mice treated with IR. In conclusion, HemoHIM may be a beneficial supplement during radiotherapy for enhancing the antitumor efficacy.
Park
Hae-Ran
HR
Radiation Research Division for Bio-Technology, Advanced Radiation Technology Institute, Jeongeup Campus of Korea Atomic Energy Research Institute, Jeonbuk, Republic of Korea.
Ju
Eun-Jin
EJ
Jo
Sung-Kee
SK
Jung
Uhee
U
Kim
Sung-Ho
SH
D029969:Angelica; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D017024:Chemotherapy, Adjuvant; D031048:Cnidium; D003208:Concanavalin A; D005260:Female; D007376:Interleukin-2 / Q000378:metabolism; D007694:Killer Cells, Natural / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D019684:Magnoliopsida; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008934:Mitogens; D029596:Paeonia; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018517:Plant Roots; D027343:Rhizome; D013154:Spleen / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D007376:Interleukin-2; D008934:Mitogens; D010936:Plant Extracts; D014409:Tumor Necrosis Factor-alpha; D003208:Concanavalin A